Histoplasmosis and Blastomycosis in Solid Organ Transplant Recipients
AbstractHistoplasmosis and blastomycosis are geographically restricted dimorphic fungi that cause infection after the conidia produced in the mold phase are inhaled into the lungs. In the lungs, at 37 °C, these organisms undergo transformation into the yeast phase. In transplant recipients, infection can occur by exposure to the mold in the environment, by reactivation of infection that had occurred previously and had been controlled by the host until immunosuppressive medications were given post-transplantation, and finally by transmission from the donor organ in the case of histoplasmosis. In transplant recipients, disseminated infection is common, and pulmonary infection is more likely to be severe than in a non-immunosuppressed person. Diagnosis has been improved, allowing earlier treatment, with the use of rapid antigen tests performed on serum and urine. Initial treatment, for all but the mildest cases of acute pulmonary histoplasmosis, should be with a lipid formulation of amphotericin B. After clinical improvement has occurred, step-down therapy with itraconazole is recommended for a total of 12 months for most transplant recipients, but some patients will require long-term suppressive therapy to prevent relapse of disease. View Full-Text
Share & Cite This Article
Kauffman, C.A.; Miceli, M.H. Histoplasmosis and Blastomycosis in Solid Organ Transplant Recipients. J. Fungi 2015, 1, 94-106.
Kauffman CA, Miceli MH. Histoplasmosis and Blastomycosis in Solid Organ Transplant Recipients. Journal of Fungi. 2015; 1(2):94-106.Chicago/Turabian Style
Kauffman, Carol A.; Miceli, Marisa H. 2015. "Histoplasmosis and Blastomycosis in Solid Organ Transplant Recipients." J. Fungi 1, no. 2: 94-106.